The medication may be prescribed to adults living with obesity, defined as having a Body Mass Index of 30 or greater
[1] [26] This reduces the risk of hypoglycaemia, though this risk increases significantly when used in combination with insulin or sulfonylureas, which may require dose reduction of these medications
Understanding what is in development provides context for future choices
However, 7 cross sectional studies examining acute effects of the GLP-1-based therapies 37,38,39,40,41,42,43 found a significant increase in % FMD following GLP-1-based interventions (mean difference in the changes from baseline: 2.58 [1.68, 3.53] %
Hoboken, NJ: Wiley-Blackwell (1989)
Ask your Mochi provider about brand-name alternatives and check your insurance coverage for Wegovy, Ozempic, or Mounjaro